At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, 4-Period, Crossover Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With Hypercholesterolemia
In Brief
A Phase 1 clinical trial evaluating Comparator: niacin + laropiprant, Comparator: niacin, and 2 other interventions for Hypercholesterolemia. Completed, enrolled 26 participants.
Detailed Summary
The purpose of this study is to evaluate the potential effects of ER niacin/laropiprant, ER niacin, laropiprant, and placebo over the course of seven days on urinary levels of a metabolite of thromboxane A2 (TxA2), as a marker of in vivo platelet reactivity.
Study Details
Timeline
Interventions
ER niacin 2 g/laropiprant 40 mg tablet once daily for 7 days
ER niacin 2 g tablet once daily for 7 days
laropiprant 40 mg once daily for 7 days
matching placebo tablets for each of the interventions once daily for 7 days